(1)Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
(2)Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.
(3)Femara is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body. Side effects from include a lowered sex drive and continuous use can lead to lowered lipid function and an impaired immune system.       

Usage:

Letrozol has a 2-4 day half-life, and it needs to be taken for up to 60 days to get a steady blood plasma level, using Letrozolesat such a low dose does happen to make it a very good economic choice compared with other aromatase inhibitors.
 

Effects:

Letrozol has been shown to delay the fusing of the growth plates in mice. When used in combination 
with hormone, letrozol has been shown effective in one adolescent boy with a short stature; Letrozol
has also been used to treat endometriosis a C17 α-alkylation which allows the hormone to survive f
irst-pass liver metabolism when ingested. It is because of this that is also sold in tablet form.

COA: